Filing Details

Accession Number:
0001562180-24-000581
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-24 16:50:28
Reporting Period:
2024-01-22
Accepted Time:
2024-01-24 16:50:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1314102 Eyepoint Pharmaceuticals Inc. EYPT Laboratory Analytical Instruments (3826) 262774444
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1779458 Scott David Jones C/O Eyepoint Pharmaceuticals, Inc.
480 Pleasant Street
Watertown MA 02472
Svp & Chief Commercial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-22 28,750 $10.13 66,712 No 4 M Direct
Common Stock Acquisiton 2024-01-22 5,416 $11.47 72,128 No 4 M Direct
Common Stock Disposition 2024-01-22 5,416 $22.24 66,712 No 4 S Direct
Common Stock Disposition 2024-01-22 28,750 $22.69 37,962 No 4 S Direct
Common Stock Acquisiton 2024-01-23 400 $12.90 38,362 No 4 M Direct
Common Stock Acquisiton 2024-01-23 500 $3.26 38,862 No 4 M Direct
Common Stock Disposition 2024-01-23 400 $25.00 38,462 No 4 S Direct
Common Stock Disposition 2024-01-23 500 $25.00 37,962 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-01-22 5,416 $0.00 5,416 $11.47
Common Stock Stock Option (Right to Buy) Disposition 2024-01-22 28,750 $0.00 28,750 $10.13
Common Stock Stock Option (Right to Buy) Disposition 2024-01-23 400 $0.00 400 $12.90
Common Stock Stock Option (Right to Buy) Disposition 2024-01-23 500 $0.00 500 $3.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,584 2031-11-01 No 4 M Direct
31,250 2032-02-09 No 4 M Direct
24,225 2030-02-28 No 4 M Direct
91,155 2033-01-05 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $23.04. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option to purchase will vest and become exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
  4. The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.
  5. The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
  6. The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.